Now, generic versions sell for $69 monthly or less (Goldman & Ward, 2024)
The widespread interest in GLP-1 receptor agonists for weight loss, particularly amid drug shortages, has renewed clinical and regulatory attention to their safety profile, yet the clinical profile of acute exposures remains poorly understood, wrote first author Jordan Miller, a researcher with The University of Texas at San Antonio, and colleagues
And if they do, unfortunately, itll create a worse black market than there is now
Leanne Owens, a physician assistant at the practice, said she prescribed 10 of her patients compounded versions of the weight loss drugs after the state stopped covering the brand-name versions for state employees in April
Freezing: This is a more nuanced topic